Cargando…

A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation

Even with its high RBE and >20 years history, there had been no breast cancer clinical trial using carbon-ion radiotherapy. We started a Phase I trial of carbon ion radiotherapy for Stage I breast cancer in 2013. This article describes the clinical and pathological evaluation of this study. Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Karasawa, Kumiko, Omatsu, Tokuhiki, Arakawa, Atsushi, Yamamoto, Naohito, Ishikawa, Takashi, Saito, Mitsue, Fukuda, Shigekazu, Kamada, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530622/
https://www.ncbi.nlm.nih.gov/pubmed/30805611
http://dx.doi.org/10.1093/jrr/rry113
_version_ 1783420691049086976
author Karasawa, Kumiko
Omatsu, Tokuhiki
Arakawa, Atsushi
Yamamoto, Naohito
Ishikawa, Takashi
Saito, Mitsue
Fukuda, Shigekazu
Kamada, Tadashi
author_facet Karasawa, Kumiko
Omatsu, Tokuhiki
Arakawa, Atsushi
Yamamoto, Naohito
Ishikawa, Takashi
Saito, Mitsue
Fukuda, Shigekazu
Kamada, Tadashi
author_sort Karasawa, Kumiko
collection PubMed
description Even with its high RBE and >20 years history, there had been no breast cancer clinical trial using carbon-ion radiotherapy. We started a Phase I trial of carbon ion radiotherapy for Stage I breast cancer in 2013. This article describes the clinical and pathological evaluation of this study. Patients with low-risk Stage I breast cancer were eligible. A dose escalation study was designed, with dose levels of 48.0, 52.8 or 60.0 Gy relative biological effectiveness (RBE) administered in four fractions within 1 week. Three months after radiotherapy, the patients underwent tumor excision for pathological evaluation. Between April 2013 and December 2014, three cases receiving 48 Gy (RBE), three cases receiving 52.8 Gy (RBE) and one case receiving 60 Gy (RBE) underwent this protocol. No adverse effects were observed except for Grade 1 acute skin reaction in four cases. Pathological evaluation revealed that all four cases with doses of 52.8 Gy (RBE) and 60.0 Gy (RBE) achieved Grade 2b or more, but only two cases reached Grade 3. At the end of 2017, all cases were alive without recurrence or late had not caused any late adverse reaction. Carbon ion radiotherapy for Stage I breast cancer seems to be safe, and we found that it did not reach enough treatment effect 3 months after the treatment.
format Online
Article
Text
id pubmed-6530622
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-65306222019-05-28 A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation Karasawa, Kumiko Omatsu, Tokuhiki Arakawa, Atsushi Yamamoto, Naohito Ishikawa, Takashi Saito, Mitsue Fukuda, Shigekazu Kamada, Tadashi J Radiat Res Regular Paper Even with its high RBE and >20 years history, there had been no breast cancer clinical trial using carbon-ion radiotherapy. We started a Phase I trial of carbon ion radiotherapy for Stage I breast cancer in 2013. This article describes the clinical and pathological evaluation of this study. Patients with low-risk Stage I breast cancer were eligible. A dose escalation study was designed, with dose levels of 48.0, 52.8 or 60.0 Gy relative biological effectiveness (RBE) administered in four fractions within 1 week. Three months after radiotherapy, the patients underwent tumor excision for pathological evaluation. Between April 2013 and December 2014, three cases receiving 48 Gy (RBE), three cases receiving 52.8 Gy (RBE) and one case receiving 60 Gy (RBE) underwent this protocol. No adverse effects were observed except for Grade 1 acute skin reaction in four cases. Pathological evaluation revealed that all four cases with doses of 52.8 Gy (RBE) and 60.0 Gy (RBE) achieved Grade 2b or more, but only two cases reached Grade 3. At the end of 2017, all cases were alive without recurrence or late had not caused any late adverse reaction. Carbon ion radiotherapy for Stage I breast cancer seems to be safe, and we found that it did not reach enough treatment effect 3 months after the treatment. Oxford University Press 2019-05 2019-02-26 /pmc/articles/PMC6530622/ /pubmed/30805611 http://dx.doi.org/10.1093/jrr/rry113 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Regular Paper
Karasawa, Kumiko
Omatsu, Tokuhiki
Arakawa, Atsushi
Yamamoto, Naohito
Ishikawa, Takashi
Saito, Mitsue
Fukuda, Shigekazu
Kamada, Tadashi
A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation
title A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation
title_full A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation
title_fullStr A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation
title_full_unstemmed A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation
title_short A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation
title_sort phase i clinical trial of carbon ion radiotherapy for stage i breast cancer: clinical and pathological evaluation
topic Regular Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530622/
https://www.ncbi.nlm.nih.gov/pubmed/30805611
http://dx.doi.org/10.1093/jrr/rry113
work_keys_str_mv AT karasawakumiko aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT omatsutokuhiki aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT arakawaatsushi aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT yamamotonaohito aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT ishikawatakashi aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT saitomitsue aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT fukudashigekazu aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT kamadatadashi aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT karasawakumiko phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT omatsutokuhiki phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT arakawaatsushi phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT yamamotonaohito phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT ishikawatakashi phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT saitomitsue phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT fukudashigekazu phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT kamadatadashi phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation
AT phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation